.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cipla
US Department of Justice
Cerilliant
Citi
McKinsey
Teva
Mallinckrodt
Covington
UBS

Generated: November 24, 2017

DrugPatentWatch Database Preview

J And J Company Profile

« Back to Dashboard

What is the competitive landscape for J AND J, and when can generic versions of J AND J drugs launch?

J AND J has thirty-two approved drugs.

There are nine US patents protecting J AND J drugs.

There are one hundred and eleven patent family members on J AND J drugs in forty-three countries and thirteen supplementary protection certificates in seven countries.

Summary for J And J

International Patents:111
US Patents:9
Tradenames:25
Ingredients:12
NDAs:32
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc
IMODIUM
loperamide hydrochloride
CAPSULE;ORAL017690-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
SUDAFED 24 HOUR
pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020021-002Dec 15, 1992OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC ALLERGY
cetirizine hydrochloride
TABLET;ORAL019835-003Nov 16, 2007OTCYesNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC-D 12 HOUR
cetirizine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021150-002Nov 9, 2007OTCYesYes► Subscribe► SubscribeY ► Subscribe
J And J Consumer Inc
IMODIUM
loperamide hydrochloride
CAPSULE;ORAL017694-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
TYLENOL
acetaminophen
SUPPOSITORY;RECTAL017756-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
CHILDREN'S MOTRIN
ibuprofen
TABLET, CHEWABLE;ORAL020601-001Nov 15, 1996OTCYesNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC HIVES RELIEF
cetirizine hydrochloride
TABLET;ORAL019835-006Nov 16, 2007OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-002Dec 17, 2007OTCYesYes► Subscribe► SubscribeY► Subscribe
J And J Consumer Inc
JUNIOR STRENGTH MOTRIN
ibuprofen
TABLET;ORAL020602-001Jun 10, 1996OTCNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for J And J

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET, CHEWABLE;ORAL020606-001Jun 26, 1996► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET, CHEWABLE;ORAL020606-001Jun 26, 1996► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM A-D
loperamide hydrochloride
SOLUTION;ORAL019487-001Mar 1, 1988► Subscribe► Subscribe
J And J Consumer Inc
CHILDREN'S MOTRIN
ibuprofen
SUSPENSION/DROPS;ORAL020603-001Jun 10, 1996► Subscribe► Subscribe
J And J Consumer Inc
CHILDREN'S MOTRIN
ibuprofen
TABLET, CHEWABLE;ORAL020601-001Nov 15, 1996► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET;ORAL021140-001Nov 30, 2000► Subscribe► Subscribe
J And J Consumer Inc
SUDAFED 24 HOUR
pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020021-002Dec 15, 1992► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-001Sep 24, 1998► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-001Sep 24, 1998► Subscribe► Subscribe
J And J Consumer Inc
SUDAFED 24 HOUR
pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020021-002Dec 15, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for J AND J drugs

Drugname Dosage Strength Tradename Submissiondate
cetirizine hydrochloride
Syrup5 mg/5 mL
ZYRTEC
3/19/2007
cetirizine hydrochloride
Chewable Tablets5 mg and 10 mg
ZYRTEC
3/25/2005
calcium carbonate/ famotadine/ magnesium hydroxide
Chewable Tablets800 mg/ 10 mg/ 165 mg (OTC)
PEPCID COMPLETE
11/1/2004

Non-Orange Book Patents for J And J

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,060,730Rapidly absorbed liquid compositions► Subscribe
6,489,329 Pharmaceutical compositions for the treatment of rhinitis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for J And J Drugs

Country Document Number Estimated Expiration
Japan2004536829► Subscribe
Spain2184293► Subscribe
Austria259236► Subscribe
Australia723364► Subscribe
El Salvador1997000026► Subscribe
New Zealand504944► Subscribe
Canada2311039► Subscribe
Japan2007176958► Subscribe
Russian Federation2004101231► Subscribe
United Kingdom2311940► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for J And J Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008006,C0933372Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
00125Netherlands► SubscribePRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
C/GB98/013United Kingdom► SubscribePRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
2014 00050Denmark► SubscribePRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
AstraZeneca
Dow
Fuji
Accenture
Teva
Citi
Harvard Business School
Novartis
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot